Literature DB >> 21447567

Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study.

Katherine P Liao1, Michael E Weinblatt, Jing Cui, Christine Iannaccone, Lori B Chibnik, Bing Lu, Jonathan S Coblyn, Nancy A Shadick, Daniel H Solomon.   

Abstract

OBJECTIVE: Treatment algorithms in RA include factors associated with poor prognosis; however, many patients remain erosion free despite years of disease. Our objective was to characterize the group of RA patients without erosions and identify its clinical predictors.
METHODS: Our study was conducted within a prospective observational cohort of RA patients recruited from the outpatient practice of an academic medical centre. We studied patients with bilateral hand radiographs at cohort baseline and 2-year follow-up assessed with Sharp/van der Heijde scores (SHS). The primary outcome was erosion-free status at baseline and 2-year follow-up. We assessed baseline values of the following as potential correlates: age at RA onset, gender, RA duration, BMI, 28-joint DAS (DAS-28), CRP, anti-CCP status, tender and swollen joint counts, functional status [multidimensional HAQ (MDHAQ)], tobacco use and RA treatments. Variables with P ≤ 0.25 in the univariate analyses were assessed using backward selection in multivariable logistic regression models.
RESULTS: Of the 271 subjects included, 21% (n = 56) were considered erosion free. Forty-six per cent (n = 26) of this group was anti-CCP positive compared with 56% (n = 121) in subjects with erosions present. Mean RA duration for erosion-free subjects was 3.9 years compared with 4.6 years in erosive subjects. Treatments for RA did not differ between the two groups. In the multivariable-adjusted analysis, significant predictors of erosion-free status were younger age at onset and shorter RA duration.
CONCLUSION: In our cohort, 21% of subjects were erosion free at baseline and 2 years. Few baseline clinical characteristics significantly predicted erosion-free status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447567      PMCID: PMC3133482          DOI: 10.1093/rheumatology/ker129

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  31 in total

1.  Robustness and generalizability of smallest detectable difference in radiological progression.

Authors:  M N Lassere; D van der Heijde; K Johnson; K Bruynesteyn; E Molenaar; A Boonen; A Verhoeven; P Emery; M Boers
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

2.  How to read radiographs according to the Sharp/van der Heijde method.

Authors:  D van der Heijde
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

3.  Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials.

Authors:  M N Lassere; D van der Heijde; K R Johnson; M Boers; J Edmonds
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

4.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.

Authors:  Henk Visser; Saskia le Cessie; Koen Vos; Ferdinand C Breedveld; Johanna M W Hazes
Journal:  Arthritis Rheum       Date:  2002-02

Review 5.  Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages.

Authors:  S Boini; F Guillemin
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

6.  Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  B Combe; M Dougados; P Goupille; A Cantagrel; J F Eliaou; J Sibilia; O Meyer; J Sany; J P Daurès; A Dubois
Journal:  Arthritis Rheum       Date:  2001-08

7.  Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.

Authors:  Christine K Iannaccone; Yvonne C Lee; Jing Cui; Michelle L Frits; Roberta J Glass; Robert M Plenge; Daniel H Solomon; Michael E Weinblatt; Nancy A Shadick
Journal:  Rheumatology (Oxford)       Date:  2010-09-16       Impact factor: 7.580

8.  The prognostic value of baseline erosions in undifferentiated arthritis.

Authors:  Mohamed M Thabet; Thomas W J Huizinga; Désirée M van der Heijde; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2009-10-15       Impact factor: 5.156

9.  Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study.

Authors:  Natacha Courvoisier; Maxime Dougados; Alain Cantagrel; Philippe Goupille; Olivier Meyer; Jean Sibilia; Jean Pierre Daures; Bernard Combe
Journal:  Arthritis Res Ther       Date:  2008-09-04       Impact factor: 5.156

10.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.

Authors:  G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2008-05-19       Impact factor: 19.103

View more
  10 in total

1.  Clinical characteristics of RA patients with secondary SS and association with joint damage.

Authors:  Lindsay E Brown; Michelle L Frits; Christine K Iannaccone; Michael E Weinblatt; Nancy A Shadick; Katherine P Liao
Journal:  Rheumatology (Oxford)       Date:  2014-10-13       Impact factor: 7.580

2.  Rheumatoid arthritis quality measures and radiographic progression.

Authors:  Sonali P Desai; Chih-Chin Liu; Heather Tory; Tabatha Norton; Michelle Frits; Siri Lillegraven; Michael Weinblatt; Jonathan Coblyn; Jinoos Yazdany; Nancy Shadick; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2014-01-25       Impact factor: 5.532

3.  [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Authors:  K Krüger; J Wollenhaupt; K Albrecht; R Alten; M Backhaus; C Baerwald; W Bolten; J Braun; H Burkhardt; G Burmester; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; J Kuipers; A Krause; H-M Lorenz; B Manger; H Nüßlein; H-G Pott; A Rubbert-Roth; M Schneider; C Specker; H Schulze-Koops; H-P Tony; S Wassenberg; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

4.  Assessment of synovitis to predict bone erosions in rheumatoid arthritis.

Authors:  Serena Bugatti; Antonio Manzo; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-08       Impact factor: 5.346

5.  Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis.

Authors:  You-Jung Ha; Dong Woo Han; Ji Hyoun Kim; Sang Wan Chung; Eun Ha Kang; Yeong Wook Song; Yun Jong Lee
Journal:  Dis Markers       Date:  2018-11-14       Impact factor: 3.434

Review 6.  Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.

Authors:  James M Gwinnutt; Maud Wieczorek; Giulio Cavalli; Andra Balanescu; Heike A Bischoff-Ferrari; Annelies Boonen; Savia de Souza; Annette de Thurah; Thomas E Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja Stamm; Karen Walker-Bone; Joep Welling; Mirjana I Zlatković-Švenda; Francis Guillemin; Suzanne M M Verstappen
Journal:  RMD Open       Date:  2022-03

7.  Distribution of erosions in hands and feet at the time for the diagnosis of RA and during 8-year follow-up.

Authors:  Maria L Andersson; B Svensson; K Forslind
Journal:  Clin Rheumatol       Date:  2020-10-23       Impact factor: 2.980

8.  Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment.

Authors:  B Fautrel; H W Nab; Y Brault; G Gallo
Journal:  RMD Open       Date:  2015-07-28

9.  Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Authors:  Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar F Petersson; Pierre Geborek; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

10.  Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.

Authors:  Karen Hambardzumyan; Rebecca J Bolce; Saedis Saevarsdottir; Kristina Forslind; Johan K Wallman; Scott E Cruickshank; Eric H Sasso; David Chernoff; Ronald F van Vollenhoven
Journal:  RMD Open       Date:  2016-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.